• Je něco špatně v tomto záznamu ?

Expression of cancer stem cells markers in urinary bladder urothelial carcinoma and its precursor lesions

J. Hacek, A. Brisuda, M. Babjuk, J. Zamecnik

. 2021 ; 165 (3) : 316-321. [pub] 20200518

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22005989

BACKGROUND: Cancer stem cells (CSC) and their role in tumorigenesis of various solid tumors have been studied in past decades. Urothelial CSC were first identified 10 years ago and subsequent studies have been performed with the aim to identify reliable markers of CSC. So far, a few studies have investigated a relationship between CSC markers expression in urothelial carcinoma tissue and histopathological characteristics of the tumor. METHODS: In our study, we evaluated an immunoexpression of the CSC markers CD24, CD44, CD66 and CD133 in tissue sections of urothelial carcinoma (all tumor grades and stages were included), urothelial carcinoma in situ and non-neoplastic urothelium, totally 218 specimens were enrolled. RESULTS: All studied molecules were expressed either in tumor tissue and non-neoplastic urothelium. Urothelial carcinomas of higher tumor grade and stage expressed molecules CD24 and CD133 significantly more frequently whereas molecules CD44 and CD66 did not show significant association with tumor histopathological features. CONCLUSIONS: Our results showed that studied molecules are not suitable for direct detection of CSC in urothelial carcinoma tissue sections, but an expression of molecules CD24 and CD133 is significantly related to urothelial carcinoma grade and stage, which are both important prognostic indicators and therefore an expression of these markers might have a potential prognostic value.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22005989
003      
CZ-PrNML
005      
20220224154536.0
007      
ta
008      
220207s2021 xr a f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2020.017 $2 doi
035    __
$a (PubMed)32424373
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Háček, Jaromír $7 xx0236643 $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
245    10
$a Expression of cancer stem cells markers in urinary bladder urothelial carcinoma and its precursor lesions / $c J. Hacek, A. Brisuda, M. Babjuk, J. Zamecnik
504    __
$a Literatura
520    9_
$a BACKGROUND: Cancer stem cells (CSC) and their role in tumorigenesis of various solid tumors have been studied in past decades. Urothelial CSC were first identified 10 years ago and subsequent studies have been performed with the aim to identify reliable markers of CSC. So far, a few studies have investigated a relationship between CSC markers expression in urothelial carcinoma tissue and histopathological characteristics of the tumor. METHODS: In our study, we evaluated an immunoexpression of the CSC markers CD24, CD44, CD66 and CD133 in tissue sections of urothelial carcinoma (all tumor grades and stages were included), urothelial carcinoma in situ and non-neoplastic urothelium, totally 218 specimens were enrolled. RESULTS: All studied molecules were expressed either in tumor tissue and non-neoplastic urothelium. Urothelial carcinomas of higher tumor grade and stage expressed molecules CD24 and CD133 significantly more frequently whereas molecules CD44 and CD66 did not show significant association with tumor histopathological features. CONCLUSIONS: Our results showed that studied molecules are not suitable for direct detection of CSC in urothelial carcinoma tissue sections, but an expression of molecules CD24 and CD133 is significantly related to urothelial carcinoma grade and stage, which are both important prognostic indicators and therefore an expression of these markers might have a potential prognostic value.
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a antigen CD24 $7 D051927
650    12
$a karcinom z přechodných buněk $7 D002295
650    _2
$a lidé $7 D006801
650    _2
$a nádorové kmenové buňky $7 D014411
650    _2
$a močový měchýř $7 D001743
650    12
$a nádory močového měchýře $7 D001749
655    _2
$a časopisecké články $7 D016428
700    1_
$a Brisuda, Antonín, $d 1980- $7 xx0208968 $u Department of Urology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Babjuk, Marko, $d 1961- $7 jn20020716353 $u Department of Urology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Zámečník, Josef, $d 1974- $7 xx0037787 $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 165, č. 3 (2021), s. 316-321
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32424373 $y Pubmed
910    __
$a ABA008 $b A 1502 $c A 1502 $y p $z 0
990    __
$a 20220207 $b ABA008
991    __
$a 20220224154524 $b ABA008
999    __
$a ok $b bmc $g 1763639 $s 1157142
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 165 $c 3 $d 316-321 $e 20200518 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20220207

Najít záznam

Citační ukazatele

Možnosti archivace